Connor Clark & Lunn Investment Management Ltd. Has $2.81 Million Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 72.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,886 shares of the biotechnology company’s stock after selling 424,988 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.07% of ADMA Biologics worth $2,811,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ADMA. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the 3rd quarter worth $31,000. National Bank of Canada FI acquired a new stake in shares of ADMA Biologics during the third quarter worth $35,000. GAMMA Investing LLC increased its holdings in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 967 shares during the last quarter. Vision Financial Markets LLC bought a new stake in ADMA Biologics in the fourth quarter valued at about $51,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics in the third quarter valued at about $62,000. 75.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of ADMA stock opened at $18.67 on Tuesday. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of 66.68 and a beta of 0.60. ADMA Biologics, Inc. has a 12-month low of $5.88 and a 12-month high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a fifty day moving average of $16.66 and a 200-day moving average of $17.97.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.